The psoriasis drug market size was valued at USD 23.40 billion in 2025 and is projected to grow from USD 25.97 billion in 2026 to USD 61.24 billion by 2034 at a CAGR of 11.32% during the forecast period (2026-2034). North America dominated the psoriasis drug market with a market share of 41.8% in 2025.
Psoriasis drugs are pharmaceutical therapies used to manage psoriasis, a chronic autoimmune skin disorder characterized by rapid skin cell growth and inflammation. These treatments include topical medications, systemic therapies, biologics, and oral small-molecule drugs that help reduce inflammation, control immune system activity, relieve symptoms, and improve skin appearance. They are prescribed based on disease severity, patient condition, and treatment response.
Download a Free Sample To learn more about this report,
Growing Adoption of Biologics and Targeted Therapies
The psoriasis drug market trends are being driven by the increasing adoption of biologic therapies, targeted treatments, and personalized medicine for managing moderate-to-severe psoriasis. Rising awareness of chronic autoimmune diseases, earlier diagnosis, and improved access to dermatology care are encouraging more patients to seek advanced treatment options. Pharmaceutical companies are focusing on developing interleukin (IL)-17, IL-23, and TNF inhibitor therapies that provide better disease control with fewer side effects and longer-lasting results. At the same time, oral targeted therapies and biosimilars are expanding treatment choices by improving affordability and accessibility. Digital health platforms and teledermatology services are also helping patients receive timely consultations, monitor treatment progress, and improve long-term disease management, supporting better clinical outcomes and patient adherence.
These developments indicate that biologics, targeted immune therapies, biosimilars, and personalized treatment approaches will remain the key Psoriasis Drug market trends, improving treatment effectiveness, expanding patient access, and supporting long-term growth in the global psoriasis therapeutics industry.
Rising Prevalence of Psoriasis and Advancements in Biologic Therapies
The psoriasis drug market is expanding due to the increasing prevalence of psoriasis and growing demand for advanced biologic and targeted therapies. Rising awareness of autoimmune disorders, improved diagnostic rates, and greater access to specialized dermatology care are encouraging early treatment adoption. Pharmaceutical companies are continuously developing biologics, biosimilars, and oral therapies that offer improved efficacy and long-term disease management. These advancements are significantly contributing to psoriasis drug market growth by improving treatment outcomes and expanding therapeutic options for patients worldwide.
High Treatment Costs and Limited Accessibility
The psoriasis drug market faces challenges due to the high cost of biologic therapies, limited reimbursement coverage in several regions, and unequal access to advanced treatments. Many biologic drugs require long-term administration and regular monitoring, increasing the overall financial burden on patients and healthcare systems. In addition, regulatory hurdles and pricing pressures continue to influence the commercial availability of innovative therapies. Recent psoriasis drug market analysis indicates that affordability and reimbursement limitations remain major barriers to broader treatment adoption, particularly in low- and middle-income countries.
Growing Development of Targeted Therapies and Biosimilars
The psoriasis drug market is expected to benefit from increasing investment in targeted biologics, biosimilars, and precision medicine approaches for autoimmune diseases. Continuous research on interleukin inhibitors, Janus kinase (JAK) inhibitors, and next-generation immunotherapies is creating new opportunities for effective disease management. Expanding healthcare infrastructure and rising awareness of chronic skin disorders in emerging economies are also supporting broader treatment adoption. These developments are expected to strengthen the psoriasis drug market size by increasing the availability of innovative and cost-effective therapeutic options.
Long-Term Safety Monitoring and Treatment Adherence
The psoriasis drug market continues to face challenges related to long-term safety monitoring, patient adherence, and variability in treatment response. Since psoriasis is a chronic autoimmune condition, many patients require lifelong therapy, making continuous monitoring for adverse effects and treatment effectiveness essential. Healthcare providers must also address issues such as therapy switching, medication adherence, and individualized treatment selection. According to recent psoriasis drug market reports, pharmaceutical companies are increasing investments in real-world evidence studies and post-marketing surveillance to improve long-term treatment outcomes and patient safety.
Request Customizationto receive a tailored report.
Interleukin Inhibitors Segment is Projected to Register the Fastest Growth at a CAGR of 11.9%
The interleukin inhibitors segment is projected to register the fastest growth at a CAGR of 11.9% during 2026–2034. In 2025, the segment accounted for 38.6% of the global psoriasis treatment market, with a value of USD 9.03 billion. Growth is driven by their high efficacy in treating moderate-to-severe psoriasis, targeted mechanism of action, and increasing adoption of advanced biologic therapies. Continuous innovation in immunology and expanding regulatory approvals are expected to further accelerate the segment's growth.
The tumor necrosis factor inhibitors segment maintained a significant market presence due to their proven effectiveness in managing chronic inflammatory conditions and their widespread use in psoriasis treatment. The vitamin D analogues segment continues to witness steady demand as they remain a preferred topical treatment option for patients with mild-to-moderate psoriasis because of their favorable safety profile.
The corticosteroids segment remains an important therapeutic option for controlling inflammation and reducing psoriasis symptoms, particularly during flare-ups. The others segment includes emerging biologics and combination therapies that address specific patient needs and expand available treatment options.
Biologics Segment Dominated the Market with 61.3% Share in 2025
The biologics segment dominated the global psoriasis treatment market with a 61.3% share in 2025, representing a market value of USD 14.34 billion. The segment is projected to grow at a CAGR of 11.4% during 2026–2034. Its dominance is attributed to superior clinical outcomes, targeted immune modulation, and increasing adoption for moderate-to-severe psoriasis. Rising availability of innovative biologic therapies and expanding patient access continue to strengthen the segment's market position.
The corticosteroids segment continues to maintain stable demand as they provide rapid symptom relief and are widely prescribed for short-term management of psoriasis. The vitamin D analogs segment is witnessing consistent adoption owing to their effectiveness in slowing excessive skin cell growth and their frequent use in combination with topical therapies.
The others segment includes systemic therapies, combination treatments, and emerging therapeutic approaches that offer additional options for patients with varying disease severity. Ongoing research and product development continue to broaden the treatment landscape.
Parenteral Segment Dominated the Market with 55.6% Share in 2025
The parenteral segment dominated the global psoriasis treatment market with a 55.6% share in 2025, representing a market value of USD 13.01 billion. The segment is projected to grow at a CAGR of 10.8% during 2026–2034. Its dominance is driven by the increasing use of injectable biologics that provide targeted treatment, improved efficacy, and longer-lasting disease control for patients with moderate-to-severe psoriasis. Growing physician preference for biologic therapies continues to support segment growth.
The oral segment is gaining traction due to the increasing availability of advanced oral therapies that offer convenient administration and improved patient adherence. The topical segment continues to maintain strong demand as creams, ointments, and gels remain the first-line treatment option for patients with mild forms of psoriasis because of their ease of use and localized action.
Others Segment is Projected to Register the Fastest Growth at a CAGR of 10.9%
The others segment is projected to register the fastest growth at a CAGR of 10.9% during 2026–2034. In 2025, the segment accounted for 16.8% of the global psoriasis treatment market, with a value of USD 3.93 billion. Growth is driven by the expanding presence of online pharmacies, specialty pharmacies, and alternative healthcare distribution networks that improve patient access to advanced psoriasis therapies. Increasing digital healthcare adoption and home delivery services are expected to further support segment expansion.
The hospital pharmacies segment dominated the market owing to the high volume of biologic prescriptions, specialized patient care, and access to advanced treatment options through healthcare institutions. The retail pharmacies segment continues to play a significant role by improving the accessibility of prescription and over-the-counter psoriasis medications, supported by their extensive distribution network and convenient availability for patients.
Speak to an Analystto discuss market opportunities.
North America psoriasis drug market accounted for 41.8% of the global market, reaching USD 9.78 billion in 2025, and is projected to grow at a CAGR of 8.9% during the forecast period. The market is driven by a high prevalence of psoriasis, strong adoption of biologics and targeted therapies, increasing healthcare expenditure, and favorable reimbursement policies. Continuous advancements in immunology research and expanding access to innovative treatments further support regional market growth.
The US market was valued at USD 8.31 billion in 2025, making it the largest contributor in North America. Rising adoption of biologic therapies, increasing diagnosis rates, strong pharmaceutical research and development, and growing availability of advanced treatment options continue to drive market growth.
Canada's market reached USD 1.47 billion in 2025. Expanding access to specialty medications, increasing healthcare awareness, growing investments in dermatology research, and improving reimbursement coverage continue to support steady market expansion.
Europe psoriasis drug market accounted for 28.6% of the global market, reaching USD 6.69 billion in 2025, and is projected to grow at a CAGR of 8.4% during the forecast period. Increasing demand for targeted therapies, expanding healthcare infrastructure, rising awareness of chronic skin disorders, and favorable government healthcare initiatives continue to support regional market growth.
The UK market was valued at USD 1.34 billion in 2025. Growing adoption of biologic medicines, increasing access to specialized dermatology care, expanding clinical research, and rising patient awareness continue to support market growth.
Germany market accounted for USD 1.87 billion in 2025. Strong healthcare infrastructure, increasing use of innovative immunotherapies, expanding pharmaceutical investments, and growing prevalence of autoimmune skin disorders continue to drive market expansion.
Asia Pacific psoriasis drug market accounted for 19.7% of the global market, reaching USD 4.61 billion in 2025, and is projected to grow at a CAGR of 11.8% during the forecast period. Rising healthcare expenditure, improving access to advanced therapies, increasing awareness of psoriasis management, and expanding pharmaceutical manufacturing continue to accelerate regional market growth. Growing investments in biologics and biosimilars further strengthen market expansion.
Japan's market generated USD 0.83 billion in 2025. Increasing demand for innovative biologics, expanding clinical research, rising healthcare spending, and growing focus on precision medicine continue to support market growth.
China's market accounted for USD 1.94 billion in 2025, representing the largest share within Asia Pacific. Growing patient population, increasing availability of biologic therapies, expanding pharmaceutical production, and rising government support for healthcare modernization continue to drive market expansion.
Latin America psoriasis drug market accounted for 5.8% of the global market, reaching USD 1.36 billion in 2025, and is projected to grow at a CAGR of 9.6% during the forecast period. Rising healthcare investments, improving access to specialty medicines, increasing awareness of chronic dermatological disorders, and expanding pharmaceutical distribution networks continue to support regional market growth.
Brazil market accounted for USD 0.73 billion in 2025. Increasing healthcare coverage, growing demand for biologic treatments, expanding dermatology services, and rising investments in pharmaceutical manufacturing continue to support market expansion.
Middle East & Africa psoriasis drug market accounted for 4.1% of the global market, totaling USD 0.96 billion in 2025, and is projected to grow at a CAGR of 8.7% during the forecast period. Improving healthcare infrastructure, increasing diagnosis of chronic skin diseases, expanding access to advanced therapies, and growing government healthcare investments continue to support regional market growth.
The UAE market was valued at USD 0.23 billion in 2025. Rising investments in specialty healthcare, increasing adoption of innovative biologic drugs, expanding dermatology clinics, and growing patient awareness continue to drive market growth.
Africa's market reached USD 0.73 billion in 2025. Expanding healthcare access, increasing pharmaceutical investments, improving diagnosis rates, and growing awareness of psoriasis treatment continue to create long-term growth opportunities across the region.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com